FAP News TodayMachine Learning Could Help ID Those with Need for FAP Genetic Test

Leveraging Machine Learning to Accelerate FAP Diagnosis and Genetic Testing

Machine learning is poised to transform the diagnostic landscape for familial amyloid polyneuropathy (FAP), a challenging and often delayed diagnosis due to its symptom overlap with other conditions. An Italian study highlights the potential of artificial intelligence in identifying patients suspected of FAP for timely genetic testing, thereby facilitating early intervention and improved patient outcomes.

Key Points:

• Machine learning algorithms can significantly aid in the early identification of patients suspected of having familial amyloid polyneuropathy (FAP), a condition traditionally marred by diagnostic delays.
• The study conducted in Italy focused on utilizing machine learning to discern patients who should undergo genetic testing for FAP, emphasizing the need for early diagnosis in non-endemic areas.
• FAP, or hereditary transthyretin amyloidosis with polyneuropathy, is characterized by the buildup of transthyretin protein, causing damage to peripheral nerves and other tissues, including the heart.
• Key symptoms associated with FAP include heart damage, unexplained weight loss, and gastrointestinal issues, which are crucial indicators for genetic testing.
• The machine learning model, particularly XGBoost (XGB), demonstrated a 70.7% accuracy rate in distinguishing between patients with and without FAP mutations, showcasing the model’s practical utility in clinical settings.
• Factors such as ataxia, gastrointestinal symptoms, and cardiomyopathy were strongly linked to a positive genetic test for FAP, providing a clearer diagnostic pathway for physicians.
• Despite commonality in symptoms like carpal tunnel syndrome and autonomic nervous system issues among patients, machine learning helped delineate those with FAP from those without, underscoring the technology’s precision.

According to a study appearing in The Lancet Neurology, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy

More on Genetic Testing/Mutations